← Leaderboards
Emmanuel Pinteaux
University Of Kentucky
$924,346
Attributed
$1,848,692
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $315.1K · FY2014–22$500K$375K$250K$125K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$1,848,692 · 2
By mechanism
R01$1,476,827 · 1
R21$371,865 · 1
Top collaborators
- Gregory Jaye Bix7 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- Edward D Hall$10,672,048
- Greg A. Gerhardt$11,382,922
- Mark P Mattson$1,922,482
- Charles F. Mactutus$6,378,382
- Rosemarie M Booze$13,099,681
Others in their field
Top investigators on “Generations”
- Richard A Gibbs · Baylor College Of Medicine$539,942,150
- David Heimbrook · Leidos Biomedical Research, Inc.$461,253,475
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$305,871,236
- Kiran Datta · Leidos Biomedical Research, Inc.$292,634,066
- Dennis R. Burton · Scripps Research Institute$280,469,869
- Eric S Lander · Whitehead Institute For Biomedical Res$262,517,055
Research focus
GenerationsIn VitroEndotheliumExtracellular MatrixInflammatory ResponseInterleukin-1 AlphaClinical TrialsEndothelial CellsDisabilityExcitotoxicityInflammationInflammatoryInterleukin-1BrainAngiogenesisCellsChronicCerebral IschemiaAcuteCytokineBiochemicalCause Of DeathInfarctionIn Vivo
Grant awards (7)
Interleukin-1 alpha as a novel treatment for ischemic stroke$285,444
R01 · FY2022 · NS
Interleukin-1 alpha as a novel treatment for ischemic stroke$288,580
R01 · FY2021 · NS
Interleukin-1 alpha as a novel treatment for ischemic stroke$290,342
R01 · FY2020 · NS
Interleukin-1 alpha as a novel treatment for ischemic stroke$315,109
R01 · FY2019 · NS
Interleukin-1 alpha as a novel treatment for ischemic stroke$297,352
R01 · FY2018 · NS
Use of IL-1alpha to Promote Angiogenesis and Functional Recovery After Experiment$163,531
R21 · FY2015 · NS
Use of IL-1alpha to Promote Angiogenesis and Functional Recovery After Experiment$208,334
R21 · FY2014 · NS